Category: Uncategorized

Applied DNA Reports First Quarter Fiscal 2025 Financial Results and Highlights Operational Progress

February 13th, 2025

Applied DNA to Report First Quarter Fiscal 2025 Financial Results After Market Close on Thursday, February 13, 2025

February 12th, 2025

Applied DNA Announces Pricing of $6.5 Million Registered Direct Offering and Concurrent Private Placement

October 30th, 2024

Applied DNA to Report Third Quarter Fiscal 2024 Financial Results on Thursday, August 8, 2024

August 7th, 2024

Applied DNA Receives Approval for TR8™ Pharmacogenomic (PGx) Testing Service from New York State Department of Health

June 13th, 2024

Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 10th, 2024

APDN Acquires Spindle Biotech, Launches LineaIVT™ Platform

July 13th, 2023

Applied DNA Announces Receipt of International Patents on its Beacon® Secure Optical Molecular Marker Technologies

February 24th, 2020

Applied DNA Closes the Loop on Traceability for Egyptian Pima with Genotyping Assays for Cotton Authentication

May 30th, 2019